Why Biogen Stock Got Sick Today
Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was 's (NASDAQ: BIIB) turn to be atypical.
After Biogen published second-quarter figures that featured top- and bottom-line beats, the biotech's stock nevertheless took a hit. It sank by 2.4%; perhaps investors were concerned with the looming round of job cuts announced by the company.
There wasn't much to dislike in Biogen's quarterly earnings. It booked revenue of just under $2.46 billion, which -- although 5% beneath the result of the year-ago quarter -- handily beat the average prognosticator estimate of $2.37 billion.
Source Fool.com
Biogen Inc. Aktie
186,25 €
0,19 %
Biogen Inc. sticht hervor mit 52 Buy- und nur 2 Sell-Einschätzungen.
Das Kursziel von 286 € für Biogen Inc. weist auf eine Steigerung von über 50% gegenüber dem aktuellen Kurs von 186.25 € hin.
